Martin Sandelin1, Anders Berglund2, Magnus Sundström3, Patrick Micke3, Simon Ekman4, Michael Bergqvist5, Stefan Bergström5, Hirsh Koyi6, Eva Brandén6, Christer Janson7, Johan Botling3. 1. Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden martin.sandelin@medsci.uu.se. 2. Regional Cancer Center Uppsala-Örebro, Uppsala, Sweden. 3. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden Unit of Molecular Pathology, Uppsala University Hospital, Uppsala, Sweden. 4. Section of Oncology, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Uppsala, Sweden. 5. Department of Oncology, Gävle Hospital, Gävle, Sweden. 6. Department of Respiratory Medicine, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Gävle, Sweden. 7. Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden.
Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) analysis is the first molecular test introduced in the routine care of patients with non-small cell lung cancer (NSCLC). In the present study, we describe the prevalence of EGFR mutations and the adherence to testing and treatment guidelines in a population-based Swedish NSCLC cohort. MATERIALS AND METHODS: Patients with NSCLC analyzed for EGFR mutations were identified and their characteristics and survival data were retrieved. We compared the study cohort to a matched lung cancer population. RESULTS: The EGFR mutation frequency was 10%. Mutations were enriched in women and in adenocarcinoma cases. Out of patients with advanced-stage NSCLC with non-squamous histology, only 49% were referred for EGFR analysis. Out of the patients with EGFR mutation and advanced disease, only 38% received EGFR-tyrosine kinase inhibitor (TKI) in first-line therapy. CONCLUSION: The EGFR-mutated NSCLC population studied is similar to other Western populations. Surprisingly, a large proportion of patients were not referred for EGFR analysis. Out of the patients with EGFR mutation, fewer than 40% received EGFR-TKI as first-line treatment. Our results highlight the need for follow-up of treatment and diagnostic algorithms in routine healthcare. Copyright
BACKGROUND:Epidermal growth factor receptor (EGFR) analysis is the first molecular test introduced in the routine care of patients with non-small cell lung cancer (NSCLC). In the present study, we describe the prevalence of EGFR mutations and the adherence to testing and treatment guidelines in a population-based Swedish NSCLC cohort. MATERIALS AND METHODS:Patients with NSCLC analyzed for EGFR mutations were identified and their characteristics and survival data were retrieved. We compared the study cohort to a matched lung cancer population. RESULTS: The EGFR mutation frequency was 10%. Mutations were enriched in women and in adenocarcinoma cases. Out of patients with advanced-stage NSCLC with non-squamous histology, only 49% were referred for EGFR analysis. Out of the patients with EGFR mutation and advanced disease, only 38% received EGFR-tyrosine kinase inhibitor (TKI) in first-line therapy. CONCLUSION: The EGFR-mutated NSCLC population studied is similar to other Western populations. Surprisingly, a large proportion of patients were not referred for EGFR analysis. Out of the patients with EGFR mutation, fewer than 40% received EGFR-TKI as first-line treatment. Our results highlight the need for follow-up of treatment and diagnostic algorithms in routine healthcare. Copyright
Authors: Mark McKeage; Mark Elwood; Sandar Tin Tin; Prashannata Khwaounjoo; Phyu Aye; Angie Li; Karen Sheath; Phillip Shepherd; George Laking; Nicola Kingston; Christopher Lewis; Donald Love Journal: Target Oncol Date: 2017-10 Impact factor: 4.493
Authors: Anna Grenda; Bożena Jarosz; Paweł Krawczyk; Tomasz Kucharczyk; Kamila Wojas-Krawczyk; Katarzyna Reszka; Kinga Krukowska; Marcin Nicoś; Juliusz Pankowski; Maciej Bryl; Rodryg Ramlau; Barbara Kuźnar-Kamińska; Tomasz Grodzki; Aleksandra Szczęsna; Krystyna Siemiątkowska; Justyna Szumiło; Halina Batura-Gabryel; Michał Palonka; Janusz Milanowski Journal: J Thorac Dis Date: 2018-08 Impact factor: 2.895
Authors: Johanna S M Mattsson; Hans Brunnström; Verena Jabs; Karolina Edlund; Karin Jirström; Stephanie Mindus; Linnéa la Fleur; Fredrik Pontén; Mats G Karlsson; Christina Karlsson; Hirsh Koyi; Eva Brandén; Johan Botling; Gisela Helenius; Patrick Micke; Maria A Svensson Journal: BMC Cancer Date: 2016-08-05 Impact factor: 4.430
Authors: Kajsa Ericson Lindquist; Anna Karlsson; Per Levéen; Hans Brunnström; Christel Reuterswärd; Karolina Holm; Mats Jönsson; Karin Annersten; Frida Rosengren; Karin Jirström; Jaroslaw Kosieradzki; Lars Ek; Åke Borg; Maria Planck; Göran Jönsson; Johan Staaf Journal: Oncotarget Date: 2017-05-23
Authors: Phyu Sin Aye; Mark James McKeage; Sandar Tin Tin; Prashannata Khwaounjoo; J Mark Elwood Journal: PLoS One Date: 2021-05-07 Impact factor: 3.240